IMRA - Imara's sickle cell treatment shows promising action in mid-stage study

Imara (IMRA) rises 5% in premarket after announcing results from its Phase 2a trial evaluating IMR-687 in adult patients with sickle cell disease. Overall, the data demonstrated that the treatment was well tolerated as a monotherapy and in combination with hydroxyurea ((HU)) at all dose levels. No clinically significant shifts in vital signs or electrocardiogram data was observed, including no hypotension or neutropenia in either of the arms.Encouraging reductions in rate of vaso-occlusive/sickle cell-related pain crises were observed in monotherapy IMR-687 treated patients vs. placebo.Biomarker data from both monotherapy and combination groups showed improvement in markers of hemolysis (rupturing of red blood cells) with variable HbF (fetal hemoglobin) results.Data demonstrated reductions in hsCRP and NTproBNP in monotherapy IMR-687 treated patients suggest potential for lowering inflammation and cardiac stress.In 2H of 2021, the company expects additional data from Phase 2a open label extension trial and interim data from ongoing higher IMR-687 dose Phase 2b trials, Ardent and

For further details see:

Imara's sickle cell treatment shows promising action in mid-stage study